Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: AAB-003 (PF-05236812)
DRUG: AAB-003 (PF-05236812)
DRUG: AAB-003 (PF-05236812)
DRUG: AAB-003 (PF-05236812)
DRUG: AAB-003 (PF-05236812)

Sponsor

Pfizer

Collaborators

[object Object]